Dianthus Therapeutics EVP Sells $2.76M in Stock

Simrat Randhawa, EVP of the biotech company, sold over 33,000 shares at an average price of $81.48.

Mar. 14, 2026 at 2:19am

Got story updates? Submit your updates here. ›

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Executive Vice President Simrat Randhawa sold 33,830 shares of the company's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.48, for a total transaction value of $2,756,468.40.

Why it matters

The sale by Randhawa, a key executive at Dianthus, represents a significant insider transaction and could signal a shift in sentiment or strategy at the biotech firm. Insider sales are closely watched by investors as they can provide insights into management's views on the company's prospects.

The details

According to a legal filing with the SEC, Randhawa sold the 33,830 shares of Dianthus Therapeutics stock. The transaction was disclosed in a regulatory filing, which is available online. The stock was sold at an average price of $81.48 per share.

  • The stock sale transaction occurred on Thursday, March 12th, 2026.

The players

Simrat Randhawa

Executive Vice President of Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.

A clinical-stage biotechnology company developing complement therapeutics for patients with severe autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

This insider sale by a key executive at Dianthus Therapeutics is noteworthy and could signal a shift in sentiment or strategy at the company. Investors will be closely watching to see if this transaction is part of a broader trend or an isolated event.